GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Priorix ( Measles, Mumps and Rubella Vaccine, Live ) for active immunisation for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older.